The brief reign of Novo Nordisk’s Wegovy pill as the lone oral GLP-1 approved for obesity has ended as Eli Lilly’s ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

Novo Nordisk’s GLP-1 heavyweight Wegovy could soon reach many more patients in Britain after the United Kingdom’s ...

The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to ...

Amid a major corporate overhaul, Novo Nordisk is pruning the ranks at its production facility in Bloomington, Indiana, which ...

Evotec has appointed Ashiq Khan, Ph.D., as chief commercial officer, putting an | Evotec has appointed Ashiq Khan, Ph.D., as ...

Iterum took its time launching Orlynvah, debuting the drug in August 2025, almost a full year after securing approval. That ...

With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices ...

With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...

Despite a healthy roster of late-stage assets and a revenue turnaround in 2025, it’s no secret that Biogen has been seeking ...

Insulet has reinstated the chief commercial officer position nearly three years after eliminating the role to pursue more ...

Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a ...